DLBCL Prognosis Calculator

What Is the Revised IPI for DLBCL?

The revised International Prognostic Index (R-IPI) stratifies prognosis in diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus chemotherapy (R-CHOP era). Five factors each add one point: age greater than 60 years, Ann Arbor stage III or IV, elevated serum LDH, ECOG performance status 2 to 4, and more than one extranodal site of disease. The total score from 0 to 5 maps to four-year progression-free and overall survival estimates.

Four-Year Survival by Score

Score 0: about 94% four-year PFS and OS (very good prognosis). Score 1: roughly 80% PFS and 79% OS. Score 2: about 65% PFS and 67% OS. Score 3: approximately 51% PFS and 55% OS (intermediate). Scores 4 to 5: about 38% to 21% four-year survival (poor prognosis). These figures derive from R-CHOP cohort validation and support treatment intensity discussions.

Clinical Use in DLBCL

R-IPI helps oncologists communicate expected outcomes and consider clinical trial enrollment or intensified therapy for high-risk patients. It does not replace histologic review, molecular subtype testing (such as cell-of-origin), or PET response assessment. Low scores support standard R-CHOP while high scores may prompt alternative regimens.